Rakovina Therapeutics Employs Top Experts to Drive Innovation in Cancer Drug Development

Rakovina Therapeutics Inc. highlights the expertise of its Scientific Advisory Board, comprised of leaders in oncology, AI-driven drug development, and precision medicine. The board will guide the company’s research strategy and pipeline advancement. Dr. Dennis Brown, SAB Chair, brings over 35 years of experience in cancer drug discovery. Dr. Artem Cherkasov is a pioneer of the Deep Docking™ AI platform, which led to a $142 million licensing deal with Roche. Dr. Petra Hamerlik specializes in brain-penetrant DNA-damage response inhibitors. Dr. Leonard Post has experience with PARP inhibitors, and Dr. Neil Sankar contributed to FDA filings for Kadcyla and Ibrutinib. Dr. Wang Shen is the inventor of Rakovina’s candidate series and CEO of Viva Vision Biotech.

The SAB will accelerate Rakovina’s corporate strategy by rapidly validating hits, leveraging translational expertise, ensuring efficient clinical development, guiding commercialization pathways, and expanding global R&D networks. The company plans to showcase AI-designed DDR molecules, optimize its pipeline, demonstrate interim ATR compound efficacy, establish a development collaboration, and continue partnering discussions for novel drug candidates. Rakovina aims to treat DDR-driven cancers with its innovative AI-enhanced design and dual-mechanism targeting approach.

Read more at GlobeNewswire: Rakovina Therapeutics Highlights Strength of Scientific